Betatrophin is produced primarily by liver and adipose tissue, and has been recently reported as a novel hormone promoting ␤ cell proliferation and ␤ cell mass and improving glucose tolerance.
T
he association of obesity with type 2 diabetes has been largely recognized, and the major basis for this link is the ability of obesity to trigger insulin resistance (1, 2) . The pathophysiologic state involves increased basal hepatic glucose production, decreased insulin-mediated glucose utilization in target tissues, and altered pancreatic function with decreased beta cell function. Failure of beta cell function is a fundamental cause of diabetic hyperglycaemia, and thereby, to understand the molecular mechanisms controlling the plasticity of beta cells represent a crucial step to develop new beta cell-specific therapies (3, 4) .
Angiopoietin-like 8 (Angptl8) has been also named lipasin, RIFL (refeeding induced in fat and liver), and hepatocellular carcinoma-associated protein TD26 (5) (6) (7) (8) (9) (10) . It is produced primarily by liver and adipose tissue and has been recently reported as a novel hormone promoting ␤ cell proliferation and ␤ cell mass and improving glucose tolerance, the reason why it was renamed as "betatrophin" (9) . However, several recent articles have questioned the role of betatrophin on ␤ cell function. One study demonstrated that Angptl8-deficient mice did not show any alteration in glucose homeostasis when fed a chow or high fat diet (8) . Similarly, other reports indicated that Angptl8-deficient mice respond similarly to wild type mice to insulin resistance (11) and that betatrophin expression does not increase human ␤ cell replication (12) . Therefore, the current role of betatrophin on glucose homeostasis and insulin sensitivity is a matter of controversy (13, 14) .
Angptl8 seems to play also a role in lipid metabolism. For instance, Angptl8-deficient mice have impaired fatty acid uptake in white adipose tissue and reduced serum triglycerides (8, 15) , associated with both a reduction in very low density lipoprotein secretion and an increase in lipoprotein lipase activity (8, 16) . Consistently, the overexpression of hepatic betatrophin increases serum triglycerides (7, 16) . Betatrophin can also affect blood lipid profiles by mechanisms promoting Angptl3 cleavage (7), a known regulator of cholesterol metabolism in mice and humans (17, 18) . In another study betatrophin correlated significantly with plasma atherogenic lipids including total cholesterol, LDL-cholesterol and apolipoprotein B in morbidly obese and type 2 diabetic patients (19) . Finally, Angptl8 SNPs have been associated with lower LDL-and HDL-cholesterol (for review see (20) ).
Betatrophin plays a key role in the metabolic transition between fasting and refeeding as it is required to direct fatty acids into adipose tissue for storage in the fed state. In this sense, its levels are regulated by nutritional status. In the liver, its expression is suppressed by fasting and induced by refeeding (5). In humans, its serum levels showed a 35% increase 2 hours following a defined meal (21) .
The measurement of circulating betatrophin in humans has not helped to elucidate the potential role of betatrophin, but even augmented the controversy. While increased plasma betatrophin levels were found in type 1 diabetic patients (22) and in type 2 diabetic patients with (21, 23) or without obesity (24, 25) , others found that its levels were not modified in obese humans (19) or decreased in human obesity and type 2 diabetes (26). In contrast to what it is already known in obese patients, it is completely unknown if betatrophin levels are also regulated in women with anorexia, a disease with a low BMI that has been associated with endocrine disorders (27, 28) and increased inflammatory cytokines (29) . Taking into account that betatrophin is expressed in adipose tissue, we hypothesized that measuring circulating levels of betatrophin in women with conditions of extreme body mass index (BMI) would help to clarify the relevance of BMI on betatrophin. To test this hypothesis, we compared 4 groups of women with normal weight (NW), anorexia nervosa (AN), obesity (OB) and morbid obesity (M-OB). ,
Materials and Methods

Subjects
A total of 149 females participated in this study after being informed about the research and signing informed consent. 30 patients were AN, 24 were obese (OB) (BMI 30 -40 kg/m 2 ), 45 were morbidly obese (M-OB) (BMI Ͼ 40 kg/m 2 ) and 50 were healthy, NW. The anthropometric and analytical characteristics of these subjects are described in Table 1 .
Enrolment into the study occurred between January 2010 and December 2012. 
Anthropometric and body composition measurements
Anthropometric and body composition measurements were performed by bioelectrical impedance (TANITA MC-180 Multifrequency; TANITA Corporation of America, Inc, Arlington Heights, IL, USA) ( Table 1) .
Measurement of plasma betatrophin and other biochemical parameters
All blood samples were obtained after overnight fasting. In the AN group, specifically, blood samples were obtained in the second or third week in DH. The quantitative measurement of betatrophin in human plasma samples was performed using a commercial enzyme-linked immunosorbent assay (ELISA) kit (ANGPTL8 ELISA Kit CSB-EL028107HU; CUSABIO BIO-TECH CO., LTD) according to the manufacturer's instructions. This kit is specific for full-length betatrophin protein and the intra-assay and interassay variation coefficient were 8% and 10% respectively. The assay sensitive limit was 6.25 pg/ml. Plasma betatrophin levels were also assessed using a second commercial ELISA kit (SK00528 -02; Aviscera Bioscience, Inc. Santa Clara, USA) according to the manufacturer's instructions. Intraassay and interassay variation coefficient were 4%-6% and 8%-10% respectively. The absorbance from each sample was measured in duplicate using a spectrophotometric microplate reader at wavelength of 450 nm (Versamax Microplate Reader; Associates of Cape Cod Incorporated, East Falmouth, MA). The results are presented as ng/ml. Given that we did not have many plasma samples available, we measured betatrophin levels with this second kit in only 14 AN and 14 M-OB and the other two groups were not included because there were no available samples from NW and OB groups.
Insulin was analyzed by an immunoradiometric assay (IRMA) (BioSource International, Camarillo, CA, USA) in a Beckman Coulter (Fullerton, CA, USA), showing 0.3% crossreaction with proinsulin. The intra-and interassay CV were 1.9% and 6.3%, respectively. Glucose, triglycerides, total cholesterol, low density lipoprotein-cholesterol (LDL-cholesterol) and high density lipoprotein-cholesterol (HDL-cholesterol) were measured using a Dimension Autoanalyzer (Dade Behrng, Deerfield, IL, USA). The homeostatic model assessment index (HOMA-IR) was calculated following the formula (fasting plasma glucose (mg/ml) ϫ fasting plasma insulin (mU/l)/405), as described elsewhere (31) . Circulating levels of leptin were measured using enzymelinked immunosorbent assays following the manufacturers´instructions (Biovendor, Modrice, Czech Republic). The leptin assay sensitivity was 0.2 ng/ml and the interassay and intra-assay coefficients of variation were less than 7.6 and 4.4%, respectively. Thyroid-stimulating hormone (TSH), free fraction of Thyroxine (FT4) and free fraction of Triiodothyronine (FT3) were analyzed by a chemiluminescence immu- 
Statistical analysis
Statistical analyses were performed using the SPSS version 20.0 software statistical package (SPSS, Chicago, IL). Data are presented as mean Ϯ SD. When necessary, data were log or square root transformed to achieve a satisfactory fit to the normal distribution or variance homogeneity. ANOVA followed by SNK post hoc test or Kruskal-Wallis test followed by MannWhitney U test was used for group comparison as appropriate. The relationships between variables were analyzed by Pearson´s correlation (normally distributed data) or Spearman´s rank correlation (non-normally distributed data) coefficients (r). Associations between ANGPTL8 and the different anthropometric, biochemical and hormonal variables have been evaluated using multivariate linear regression. The criterion used for selecting the best model was based on Akaike Information Criterion (AIC), under the assumption that models with presence of multicollinearity are rejected. The optimal model was obtained with an automatic procedure of stepwise selection using bidirectional elimination, a combination of forward selection and backward elimination, testing at each step for variables for being excluded or included. As final step of the process we checked for multicollinearity (presence of variables highly correlated) in the explanatory variables using the variance inflation factor (VIF) and no problems were found: the VIF for all the covariates (with all possible combinations) were below 2 (the problems arise when VIF is above 5) (32). Levels of statistical significance were set at P Ͻ .05.
Results
As expected, the higher body weight of M-OB subjects was consistent with a significant increase of fat mass, BMI, fasting glucose, fasting insulinemia, HOMA index, triglycerides and leptin compared to AN and NW subjects (Table 1) . NW subjects exhibited statistically higher body weight, BMI, fat mass % and leptin than AN subjects (Table 1) .
Circulating concentrations of betatrophin were significantly higher in AN women in comparison to NW women (AN 21.5 vs NW 17.3 ng/ml, P Ͻ .01) ( Figure 1A) . Moreover, plasma betatrophin levels were significantly lower in M-OB women compared to NW women (M-OB 11.9 vs NW 17.3 ng/ml, P Ͻ .001), whereas no significant differences were detected between NW and OB women (NW 17.3 vs OB 17.3 ng/ml) ( Figure 1A ). When circulating betatrophin levels were corrected by the amount of fat mass, these differences were magnified and the ratio betatrophin/fat mass was 5 times higher in AN than in NW women ( Figure 1B ). In addition, the ratio betatrophin/fat mass was decreased in proportion to the amount of fat mass, thus, it was significantly higher in NW than OB women, and in OB than in M-OB women ( Figure 1B) .
A significant negative correlation was found between betatrophin and weight (P Ͻ .001), BMI (P Ͻ .001), fat mass % (P Ͻ .001), glucose (P Ͻ .01), insulin (P Ͻ .001), HOMA index (P Ͻ .001), triglycerides (P Ͻ .001) and leptin (P ϭ .001) ( Table 2 and Figure 2) . A significant positive correlation was found between betatrophin and HDL-cholesterol (P Ͻ .001). When correlations were performed in each individual group, we found that in NW women there was a significant positive correlation between betatrophin and HDL-cholesterol (P Ͻ .05), and in M-OB women betatrophin was negatively correlated with insulin (P Ͻ .05) and HOMA (P Ͻ .05) and positively correlated with HDL-cholesterol (P Ͻ .001) and leptin (P Ͻ .05) ( Table 3 ). In the multiple linear regression analysis, the optimal model that best explained the betatrophin data included BMI (P Ͻ .05), HDL-cholesterol (P Ͻ .05), insulin (P Ͻ .05) and FT4 (P Ͼ .05), with an adjusted R 2 of 0.30 (Table 4) . In this sense, it is important to highlight that the association was stronger for HDL-C and insulin than for BMI. An important observation is that age was statistically different between the studied groups (Table 1) and showed a negative correlation with betatrophin (Table 2 ). In order Figure 1 . Plasma betatrophin levels in anorexic (AN) (n ϭ 30), normal weight (NW) (n ϭ 50), obese (OB) (n ϭ 24) and morbidly obese (M-OB) (n ϭ 45) women (A). Ratio between circulating betatrophin (ng/ml) and fat mass (kg) in AN, NW, OB and M-OB women (B). **P Ͻ .01, ***P Ͻ .001.
to clarify if age was a factor confounding factor we next performed different analyses. First, we selected women within a range of age (20 -34 years) (Supplemental Table  1 ). By doing this, we avoided significant statistical differences in the age between the four groups of patients. When we reduced the range of age, we still saw that betatrophin levels were significantly higher in AN women when compared to NW or M-OB women (Supplemental Figure 1) . In addition, we still saw that betatrophin levels in M-OB women were significantly lower than in the other groups (Supplemental Figure 1) .
We have also performed correlations between betatrophin levels and biochemical and hormonal parameters (Supplemental Table 2 ). Our results indicated that similarly to what we observed in women with different ages, when we reduced the range of age, betatrophin was negatively correlated with weight (P Ͻ .001), BMI (P Ͻ .001), fat mass (P Ͻ .001), glucose (P Ͻ .001), insulin (P Ͻ .01), HOMA (P Ͻ .001), trglycerides (P Ͻ .05) and leptin (P Ͻ .001). The positive correlation between betatrophin and HDL-cholesterol (P Ͻ .001) was also maintained when we reduced the range of age (Supplemental Table 2 ). Finally, we have performed a multivariate linear regression model including age (Supplemental Table 3 ). This model showed that age did not explain betatrophin data. Overall, these results demonstrate that our data on betatrophin concentrations were not affected by age.
Since published results on betatrophin concentrations in humans are controversial in part due to technical issues and assay variability, we next aimed to confirm our initial results measuring betatrophin levels with a different assay (SK00528 -02; Aviscera Bioscience, Inc. Santa Clara, USA) and our results corroborated that plasma betatrophin levels were significantly higher in AN women in comparison to M-OB women (Supplemental Figure 2A) . In addition, we have also confirmed plasma betatrophin concentrations obtained with the Cusabio ELISA kit by comparison with Aviscera Bioscience ELISA kit (Supplemental Figure 2B ). With this kit, a significant negative correlation was found between betatrophin and weight (P Ͻ .001), BMI (P Ͻ .01), fat mass % (P Ͻ .01), insulin (P Ͻ .05), HOMA index (P Ͻ .05), and leptin (P Ͻ .01) (Supplemental Table 4 ). A significant positive correlation was found between betatrophin and HDL-cholesterol (P Ͻ .01) (Supplemental Table 4 ).
Discussion
Diabetes mellitus is a metabolic disease characterized by hyperglycemia caused by an insufficient functional beta cell mass. Betatrophin caused a great expectation in the field as it was initially reported to increase the rate of pancreatic beta cell proliferation, islet size and insulin content (9) . Betatrophin is highly expressed in liver and adipose tissue, and is regulated by nutritional status, since it is stimulated by feeding and reduced by fasting (5, 6) . Therefore, we hypothesized that circulating betatrophin levels might be affected by pathophysiological conditions altering body weight not necessarily associated to changes in insulin sensitivity and glucose homeostasis.
Different reports show opposite results regarding betatrophin levels in humans. Whereas some laboratories found that its levels are increased in obesity (21, 23) , others showed that obese subjects had unchanged (19) or decreased serum betatrophin levels, and they were further reduced in obese type 2 diabetic patients (26) . The explanation for these discrepancies seems to be related to the fragment recognized by the different kits and the betatrophin proteolytic regulation in vivo (33) . Although the discussion about betatrophin concentrations is often related to insulin or glucose levels, betatrophin is expressed in white adipose tissue (WAT), and thereby it seems plausible to hypothesize that the amount of fat might be important for its systemic levels. To test this hypothesis, we carried out a study in women with extreme BMIs. Although there are different studies reporting that betatrophin levels do not change (19) or increase (21, 23) in obese patients, rising doubts in the methodology of detection (33) as press.endocrine.org/journal/jcemstated above, we undertook our measurements by using ELISA from two different providers obtaining the same results. Dissimilarities between obese subject´s characteristics might offer an alternative explanation. For example, there are many uncontrolled obesity-associated changes in adipose tissue and liver that may affect betatrophin levels. For instance, the degree of inflammation, dyslipidemia or liver damage might have an impact. The fact that betatrophin is nutritionally regulated (21) also suggests that the time under fasting before blood extraction or even the nutritional composition of meals might play an important role in the regulation of this hormone.
In agreement with a previous report (26) , our results show that morbid obese women have significant lower levels when compared with NW. It is important to highlight that these differences were only significant in M-OB, when the BMI was higher than 40 kg/m 2 , whereas plasma betatrophin remained unchanged between obese (BMI 30 -40 kg/m 2 ) and NW women. Moreover, betatrophin levels were significantly increased in AN in comparison to Betatrophin and extreme BMIs J Clin Endocrinol Metab NW women. Altogether, and in contrast to our initial expectations, these results indicate that plasma betatrophin levels and fat mass are inversely regulated, with betatrophin concentrations being increased in a catabolic condition and decreased in conditions of extreme BMIs. This inverse regulation is clearer when circulating betatrophin is corrected by fat mass. These results suggest that there might be a source different to WAT to explain high levels of betatrophin in AN women and decreased levels in morbid obesity. The most likely candidate is the liver, but we cannot discard other still unknown sources of betatrophin. Another alternative explanation might be that the capacity of WAT to secrete betatrophin is compromised in conditions of obesity, in a similar way to adiponectin, and therefore the low ability of WAT to secrete betatrophin might explain the lower levels of circulating betatrophin. Further studies will be necessary to assess the role of liver and other tissues in the secretion of betatrophin, as well as to investigate the capacity of WAT to secrete this hormone under conditions of extreme BMIs. An important issue is that betatrophin concentrations were increased in AN women even though AN and NW women showed similar levels of glucose, insulin and have a similar HOMA index. These findings suggest that changes in betatrophin levels in AN women cannot be explained by different levels of insulin, glucose or changes in insulin sensitivity. This issue is also corroborated by the fact that nonmorbid obese women are hyperglycemic and insulin resistant but their plasma betatrophin levels are similar to the ones observed in NW women. However, when all women were analyzed together, betatrophin concentrations were significantly and negatively correlated with all markers of insulin resistance such as glycemia, insulinemia and HOMA. This is likely explained by the strong association between betatrophin and fasting insulin/HOMA in M-OB women, suggesting that the interaction between betatrophin and insulin/HOMA is somehow affected in morbid obesity.
In addition, when all women were analyzed together, betatrophin concentrations were significantly and positively correlated with HDL-cholesterol. In this sense, HDL-cholesterol was one of the factors that best explained betatrophin levels together with BMI, insulin and T4, being the association stronger for HDL-C and insulin than for BMI. Consistent with our findings on the strong interaction between betatrophin and HDL-cholesterol, betatrophin has been also linked to altered lipid metabolism (5, 6, 16, 34) . Mice lacking the betatrophin gene showed reduced serum triglyceride levels in response to feeding (8) and the genetic overexpression of betatrophin in the liver increases serum triglycerides (5) . Moreover, betatrophin regulates hepatic VLDL secretion (5, 8) and its levels correlate with plasma atherogenic lipids in obese and type 2 diabetic patients (19) . In our study, levels of betatrophin were positively correlated with HDL-cholesterol. For instance, in AN women, which had the highest betatrophin levels among the four studied groups, showed the highest HDL-cholesterol levels. Accordingly, M-OB women, which had the lowest betatrophin levels, showed the lowest HDL-cholesterol levels. In addition, when all women were analyzed together, betatrophin levels were positively correlated with HDL-cholesterol. In this regard, it is important to point out that when the relationship between betatrophin levels and the different parameters was analyzed in each group of the study population, this correlation with HDL-C seems to be mostly driven by the strong association seen in the M-OB group. Therefore, the interaction between betatrophin and HDL-C might be dependent of an obesity-associated factor, but this aspect will require further investigation. In summary, the present study shows that plasma betatrophin levels are increased in anorexic women and reduced in morbid obese women. Moreover, betatrophin levels are negatively correlated with weight, BMI, fat mass %, glucose, insulin, HOMA index, triglycerides and leptin, whereas it is positively correlated with HDL-cholesterol. These results suggest that metabolic status is an important regulator of circulating betatrophin levels and in addition to its putative role in beta cells, glucose homeostasis and insulin sensitivity, betatrophin might play an important role in other comorbidities associated to obesity such as dyslipidemia.
